Enveda Reports Positive Phase 1 Results for ENV-308, an Oral Therapy Designed to Support Long-Term Metabolic Health As the use of GLP-1 medications continues to expand among adults in the United States, growing attention is being directed toward a major…
Ingenia Therapeutics Begins KOSDAQ Trading to Advance Vascular-Targeted Therapy Pipeline Ingenia Therapeutics, a clinical-stage biotechnology company focused on developing next-generation vascular-targeted therapies, has announced that its shares have begun trading on South Korea’s KOSDAQ market, marking a significant milestone in…
InduPro Raises $77 Million Series B and Advances Lead Oncology Program IDP-001 Into Phase 1 Clinical Development InduPro, Inc., a biotechnology company developing a new class of therapeutics based on the spatial organization of proteins on cell surfaces, has announced…
CN Bio Secures £180,000 Innovate UK Grant to Advance Human-Relevant Organ-on-a-Chip Technology for Drug Development CN Bio, a leading developer of Organ-on-a-Chip (OOC) systems and advanced solutions designed to accelerate drug discovery and development, has announced that it has been…
Thermo Fisher Scientific Completes Large-Scale Proteomic Analysis for Landmark Parkinson’s Disease Study Thermo Fisher Scientific Inc., a global leader in scientific research services and technologies, has announced the completion of a large-scale proteomic analysis involving approximately 5,500 research samples from…
ACCESS and Johnson & Johnson Announce Multi-Year Agreement to Expand Advanced Cardiac Electrophysiology Technologies in U.S. Ambulatory Surgery Centers ACCESS, through its physician-led group purchasing organization, ACCESS Group Purchasing Organization (ACCESS GPO), has announced a new multi-year preferred portfolio agreement…
BeOne Medicines and Revolution Medicines Announce Broad Oncology Collaboration to Advance RAS-Targeted Therapies BeOne Medicines Ltd. and Revolution Medicines, Inc. have announced a multi-part strategic collaboration aimed at expanding treatment options for patients with RAS-addicted cancers. The agreement combines clinical…
Battelle Hosts National Security Commission on Emerging Biotechnology to Highlight Ohio’s Growing Biotechnology Capabilities Battelle recently welcomed members of the National Security Commission on Emerging Biotechnology (NSCEB) to its Columbus, Ohio, headquarters as part of the Commission’s national District Spotlight…
LabPMM Launches Global KMT2A Measurable Residual Disease Testing Service to Advance Precision Monitoring in Acute Leukemia LabPMM®, a subsidiary of Invivoscribe®, has announced the worldwide launch of its new KMT2A measurable residual disease (MRD) testing service, expanding access to highly…
LabPMM Launches Global KMT2A MRD Testing Service to Support Precision Monitoring and Clinical Development in Acute Leukemia LabPMM®, a global reference laboratory and subsidiary of Invivoscribe®, has announced the worldwide availability of its new KMT2A measurable residual disease (MRD) testing…
Pilatus Biosciences to Present Preclinical Data Highlighting PLT012’s Disease-Modifying Potential in COPD at ERS International Congress 2026 Pilatus Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative metabolic checkpoint immunotherapies for cancer and immune-mediated diseases, has announced that new preclinical…
Rocket Pharmaceuticals Reports Positive Early Safety Update for RP-A501 Phase 2 Trial in Danon Disease Rocket Pharmaceuticals, Inc. has announced encouraging early safety results from the first three patients treated under the modified protocol of its global pivotal Phase 2…